Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer

By afschroeder • August 18, 2026

Baclig NV, Chengappa M, Soliman AJ, Jacob S, LeVee A, Fisch S, Face C, Chaudhry S, Idossa D, Poonacha T, Huppert L, Quintal L, Melisko M, Majure M, Tsai K, Kordic A, Chien J, Mortimer J, Rugo HS, Lechner MG, Blaes A, McCann KE. Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer. Clin Breast Cancer. 2026 Jul 20;26(9):91-100. doi: 10.1016/j.clbc.2026.07.026. Epub ahead of print. PMID: 42607491.

Tags: Endocrinology, Hematology/Oncology, immune checkpoint inhibitor, immunotherapy, PD-1 PD-L1 inhibitor, Publications, toxicity

Related Posts

Annexin A1 inhibits neuronal apoptosis in amyotrophic lateral sclerosis by restraining the Hippo pathway

Zhang Y, Dong X, Shai Y, Masood A, Han D, Hu Y, He Z, Zhou Z, Jiang H. Annexin A1 inhibits neuronal apoptosis in amyotrophic[...]

Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol

Chandra MS, Gagliano-Jucá T, Shekhar S, Pencina KM, Travison TG, Garg R, McDonnell ME, Reid KF, Latham NK, Lam H, Meritus D, Yan Y, Isaza[...]

Temporal multi-omic analysis uncovers sex-biased molecular programs underlying skeletal muscle adaptation to endurance training

Many GM, Jin C, Day NJ, Iyer G, Smith G, Voos K, Sanford JA, Bareja A, Jimenez-Morales D, Leach DT, Sagendorf TJ, Ahmed A, Li[...]